Tagged with

Pharma Legal Handbook The legal framework for cannabinoid drugs, medical cannabis and opioids in Chile. Prepared in association with Carey, a leading global law firm, this is an extract from The Pharma Legal Handbook: Chile, available to purchase here for GBP 99.   Cannabinoid Drugs   1. Are Cannabinoid Drugs authorized in your…

Pharma Legal Handbook Want to know more about orphan drugs and rare diseases in Chile? Read on! Prepared in association with Carey, a leading global law firm, this is an extract from The Pharma Legal Handbook: Chile, available to purchase here for GBP 99.   1. What is the definition of Rare Diseases in…

Pharma Legal Handbook The key facts about biosimilars and biologics in Chile. Prepared in association with Carey, a leading global law firm, this is an extract from The Pharma Legal Handbook: Chile, available to purchase here for GBP 99.   1. Are biosimilar medicines considered the same as generic medicines in your country?…

Belgium Belgium’s Flanders region is a hotbed of biotech excellence, with numerous examples of university spin-offs being translated into commercial-stage companies and many of those later acquired by Big Pharma. Wouter Piepers of cluster organisation flanders.bio outlines the fundamentals behind this success story, and what potential future investors in Belgian biotech…

Hong Kong Professor Michael Yang of City University of Hong Kong (CityU) introduces the ‘HK Tech 300‘ programme he oversees, the largest university-based entrepreneurship programme in Asia. Drawing on his own experience as co-founder of Prenetics and Cellomics, biotech companies based on technologies developed in his laboratory at CityU, Professor Yang assesses…

Belgium Nipro’s Serge Kemps explains how the COVID-19 pandemic and its after-effects led the Japanese-headquartered medtech firm to diversify its offering beyond its traditional area of focus, renal care, and establish a footprint in interventional cardiology. Kemps also outlines some of the challenges of moving towards a truly value-based healthcare system…

Hong Kong Hong Kong’s Secretary for Innovation, Technology and Industry since July 2022, Professor Dong SUN is a pioneer in robotic manipulation of biological cells and robot control, whose research has led to breakthroughs in the use of robotics combined with various micro-engineering tools. Now with responsibility for developing Hong Kong into…

Belgium Karel van de Sompel of GIBBIS – the pluralistic federation of the public and private social-profit healthcare sector within the Brussels area – outlines the scope and aims of the organisation, the learnings from his near-four decades at Pfizer that can be applied in this new role, and some of…

UAE Amgen’s Mohammed Nasser casts his eye on some of the key trends affecting healthcare and the life sciences in the Middle East and Africa, including a significant maturity in uptake of digital and telehealth tools, better synchronisation of electronic medical records, and how artificial intelligence can be used to better…

Belgium Benelux is a crucial cluster for Bristol Myers Squibb (BMS), which recently started construction of its first European CAR-T cell therapy production centre at the Leiden Bio Science Park. Sally Ann McNab, the company’s general manager and VP Benelux outlines the 28-year journey that has brought her to this important…

Denmark Danish allergy specialist ALK will have a new CEO in 2024, with current incumbent Carsten Hellmann set to step down after a seven-year spell in the hot seat. Hellmann, 59, will be replaced by the comparatively youthful 45-year-old Peter Halling at the end of the year, which ALK Board Chairman…

Greece Country managers from three leading medtech multinationals give their take on the key access challenges facing medical device companies in Greece.   New Access Models “While some value-based procurement agreements have been struck in the private sector, we are struggling to gain acceptance for such agreements in the public sector.…